Development of a T-cell activation-related module with predictive value for the prognosis and immune checkpoint blockade therapy response in glioblastoma

BACKGROUND: Despite the rise in the use of immune checkpoint blockade drugs (ICBs) in recent years, there are no ICB drugs that are currently approved or under large-scale clinical trials for glioblastoma (GBM). T-cells, which mainly mediate adaptive immunity, are an important part of the tumor immu...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Zihao, Chu, Siwen, Zhu, Chen, Han, Yunhe, Liang, Qingyu, Shen, Shuai, Cheng, Wen, Wu, Anhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PeerJ Inc. 2021
Materias:
Bioinformatics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8710057/
https://www.ncbi.nlm.nih.gov/pubmed/35036121
http://dx.doi.org/10.7717/peerj.12547

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8710057/
https://www.ncbi.nlm.nih.gov/pubmed/35036121
http://dx.doi.org/10.7717/peerj.12547

Ejemplares similares